Results 31 to 40 of about 156,553 (306)
EClinicalMedicine, 2021 Background: Coronavirus disease 2019 (COVID-19) is associated with a hypercoagulable state. Limited data exist informing the relationship between anticoagulation therapy and risk for COVID-19 related hospitalization and mortality.
Sameh M. Hozayen +10 more
doaj +1 more source
Sinovenous Thrombosis: Anticoagulation Therapy
Pediatric Neurology Briefs, 1998 The value of anticoagulant therapy in a consecutive cohort 5 year study of 30 children with 32 episodes of sinovenous thrombosis (SVT) was assessed at the Hospital for Sick Children, Toronto, Canada.
J Gordon Millichap
doaj +1 more source
BMC Cardiovascular Disorders, 2023 Background The clinical benefits and risks of anticoagulation therapy in patients with chronic kidney disease (CKD) are still inconclusive. We describe the outcomes of patients with atrial fibrillation (AF) after anticoagulation therapy according to ...
Min Soo Cho +5 more
doaj +1 more source
Real-practice thromboprophylaxis in atrial fibrillation [PDF]
, 2017 This retrospective observational study was based on databases of the Local Health Authority of Treviso, Italy. It evaluated the prevalence and the effectiveness of oral anticoagulation treatment (OAT) for the management of nonvalvular atrial fibrillation
Bettiol, Alessandra +8 more
core +2 more sources
Extended Anticoagulation After Pulmonary Embolism: A Multicenter Observational Cohort Analysis
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background Pulmonary embolism (PE) has a long‐term risk of adverse events, which can be prevented by extended anticoagulation. We compared clinical characteristics and outcomes between patients treated with 2‐year extended anticoagulation and those who ...
Romain Chopard +7 more
doaj +1 more source
How we treat bleeding associated with direct oral anticoagulants [PDF]
, 2016 Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo +4 more
core +1 more source
Anticoagulant therapy with fondaparinux in a liver transplant patient with thrombosis and liver fibrosis: a case report [PDF]
, 2017 The treatment with fondaparinux is the effective and safe anticoagulant therapy in liver transplant patient on immunosuppressive therapy with arterial thrombosis, and it seems able to reduce liver fibrosis.
Cafolla, Arturo, Gentile, Giuseppe
core +1 more source
Pathways for lower extremity superficial vein thrombosis management in an academic medical center
Bleeding, Thrombosis and Vascular BiologyThere is currently no established management pathway for lower extremity superficial vein thrombosis (SVT), leading to significant uncertainty among front-line providers.
Gisoo Imani +3 more
doaj +3 more sources
Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran [PDF]
, 2015 © Otsui et al. 2015BACKGROUND: Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not required; however, a
Gorog, Diana A +8 more
core +2 more sources
BMJ Open, 2019 Objective To investigate anticoagulant adherence and its associated factors, including demographics, clinical variables, atrial fibrillation (AF) severity, knowledge, satisfaction with services, perceived barriers, perceived benefits, symptom severity ...
Tsae-Jyy Wang +6 more
doaj +1 more source